In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

If Regulus’ lead drug candidate, farabursen, gets regulatory approval ... Novartis – which has its U.S. headquarters in East Hanover – said the move will strengthen its lineup of kidney ...

The new FDA approval comes as ... for health plans and employers. Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy.

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

Regulus forged ahead with plans to start a phase 3 trial that could support a filing for accelerated approval. Novartis has identified farabursen as a good fit for its burgeoning kidney disease ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...